Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Dec 10, 2021
- Accession no.
- 0001209191-21-069159
- Filed
- Dec 10, 2021
- Trade date
- Dec 8-9, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $236.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2021 | Class A Common Stock | MOption exerciseAcquired | +28,646 | $2.47 | +$70,755.62 | 28,646 | Direct | |
| Dec 8, 2021 | Class A Common Stock | SSaleDisposed | −5,176 | $20.03F2 | −$103,675.28 | 23,470 | Direct | |
| Dec 8, 2021 | Class A Common Stock | CConversionAcquired | +5,488 | $0.00 | $0 | 28,958 | Direct | |
| Dec 8, 2021 | Class A Common Stock | SSaleDisposed | −5,488 | $20.26F4 | −$111,186.88 | 23,470 | Direct | |
| Dec 9, 2021 | Class A Common Stock | CConversionAcquired | +1,086 | $0.00 | $0 | 24,556 | Direct | |
| Dec 9, 2021 | Class A Common Stock | SSaleDisposed | −1,086 | $20.01F5 | −$21,730.86 | 23,470 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2021 | Class A Common Stock | MOption exerciseDisposed | −28,646 | $0.00 | $0 | 1,471,354 | Direct | |
| Dec 8, 2021 | Class A Common Stock | CConversionDisposed | −5,488 | $0.00 | $0 | 8,195,728 | Direct | |
| Dec 9, 2021 | Class A Common Stock | CConversionDisposed | −1,086 | $0.00 | $0 | 8,194,642 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction, representing a sale to cover the exercise price and related tax withholdings for 28,646 option shares, was executed in multiple trades at prices ranging from $20.014 to $20.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.